XXYLT1 methylation contributes to the occurrence of lung adenocarcinoma: Methylation and lung adenocarcinoma.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
08 Jan 2021
08 Jan 2021
Historique:
received:
03
03
2020
accepted:
07
12
2020
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
26
1
2021
Statut:
ppublish
Résumé
There is evidence that DNA methylation play major roles in lung cancer. In our previously study, C3 or f21 , also referred to as XXYLT1, rs2131877 polymorphism is associated with a reduced risk of lung adenocarcinoma. So, we explored the role of XXYLT1 methylation in lung adenocarcinoma. This study was conducted in 2 steps. In the first step, we recruited 15 patients with lung adenocarcinoma. Cancer tissues and para-carcinoma tissues were obtained from each of the patients. In the second step, 150 patients with lung adenocarcinom were enrolled, and cancer and normal lung tissue were obtained from each patients, respectively. The expression levels of XXYLT1 mRNA were determined, the deoxyribonucleic acid methylation status was analyzed by MassARRAY Spectrometry. The methylation data of individual units were generated by EpiTyper v1.0.5 software. The XXYLT1 mRNA expression was significantly lower in cancer tissues than in para-carcinoma and normal lung tissues. Meanwhile, the methylation rates of three CpG units (CpG_23, CpG_25, and CpG_60.61.62.63.64.65) within the XXYLT1 gene were higher in cancer tissues compared to the para-carcinoma and the normal lung tissues. This difference was particularly significant in male patients. Our results suggested that methylation of XXYLT1 may have significance in the pathogenesis of lung adenocarcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
There is evidence that DNA methylation play major roles in lung cancer. In our previously study, C3 or f21 , also referred to as XXYLT1, rs2131877 polymorphism is associated with a reduced risk of lung adenocarcinoma. So, we explored the role of XXYLT1 methylation in lung adenocarcinoma.
METHODS
METHODS
This study was conducted in 2 steps. In the first step, we recruited 15 patients with lung adenocarcinoma. Cancer tissues and para-carcinoma tissues were obtained from each of the patients. In the second step, 150 patients with lung adenocarcinom were enrolled, and cancer and normal lung tissue were obtained from each patients, respectively. The expression levels of XXYLT1 mRNA were determined, the deoxyribonucleic acid methylation status was analyzed by MassARRAY Spectrometry. The methylation data of individual units were generated by EpiTyper v1.0.5 software.
RESULTS
RESULTS
The XXYLT1 mRNA expression was significantly lower in cancer tissues than in para-carcinoma and normal lung tissues. Meanwhile, the methylation rates of three CpG units (CpG_23, CpG_25, and CpG_60.61.62.63.64.65) within the XXYLT1 gene were higher in cancer tissues compared to the para-carcinoma and the normal lung tissues. This difference was particularly significant in male patients.
CONCLUSIONS
CONCLUSIONS
Our results suggested that methylation of XXYLT1 may have significance in the pathogenesis of lung adenocarcinoma.
Identifiants
pubmed: 33429795
doi: 10.1097/MD.0000000000024150
pii: 00005792-202101080-00071
pmc: PMC7793369
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24150Subventions
Organisme : Zhejiang Provincial Medical and Health Scientific and Technical Foundation
ID : 2019KY043
Organisme : zhejiang provincial medical and health scientific and technical foundation
ID : 2020KY470
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.
Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev 2016;25:16–27.
McDermott U1, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389–95.
Ong Philip, Ost David. Diaz-Jimenez Jose Pable, Rodriguez Alicia N. Lung cancer epidemiologic changes: implications in diagnosis and therapy. Interventions in Pulmonary Medicine 2nd edCham, Switzerland: Springer International Publishing; 2018. 323–32.
Ntziachristos P, Lim JS, Sage J, et al. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell 2014;25:318–34.
Klinakis A, Lobry C, Abdel-Wahab O, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011;473:230–3.
Wang NJ, Sanborn Z, Arnett KL, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA 2001;108:17761–6.
Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154–7.
Takeuchi H, Haltiwanger RS. Significance of glycosylation in Notch signaling. Biochem Biophys Res Commun 2014;453:235–42.
Sethi MK, Buettner FF, Krylov VB, et al. Identification of glycosyltransferase 8 family members as xylosyltransferases acting on O-glucosylated notch epidermal growth factor repeats. J Biol Chem 2010;285:1582–6.
Cantarel BL, Coutinho PM, Rancurel C, et al. The carbohydrate-active enzymes database (CAZy): an expert resource for glycogenomics. Nucleic Acids Res 2009;37(Database issue):D233–8.
Lombard V, Golaconda Ramulu H, et al. The carbohydrate-active enzymes database (CAZy) in 2013. Nucleic Acids Res 2014;42(Database issue):D490–5.
Sethi MK, Buettner FF, Ashikov A, et al. Molecular cloning of a xylosyltransferase that transfers the second xylose to O-glucosylated epidermal growth factor repeats of notch. J Biol Chem 2012;287:2739–48.
Lairson LL, Henrissat B, Davies GJ, et al. Glycosyltransferases: structures, functions, and mechanisms. Annu Rev Biochem 2008;77:521–55.
Lee TV, Sethi MK, Leonardi J, et al. Negative regulation of notch signaling by xylose. PLoS Genet 2013;9:e1003547.
Sethi MK, Buettner FF, Ashikov A, et al. In vitro assays of orphan glycosyltransferases and their application to identify Notch xylosyltransferases. Methods Mol Biol 2013;1022:307–20.
Zhang Y, Gu C, Shi H, et al. Association between C3orf21, TP63 polymorphisms and environment and NSCLC in never-smoking Chinese population. Gene 2012;497:93–7.
Yang L, Wang Y, Fang M, et al. C3orf21 ablation promotes the proliferation of lung adenocarcinoma, and its mutation at the rs2131877 locus may serve as a susceptibility marker. Oncotarget 2017;8:33422–31.
Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 2007;48:1472–81.
Jacinto FV, Esteller M. MGMT hypemethylation: aprognostie foe, a predictive friend. DNA Repair (Amst) 2007;6:1155–60.
Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the prddictive value of O.-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871–4.
Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401–4.
Yu H, Takeuchi M, LeBarron J, et al. Notch-modifying xylosyltransferase structures support an SNilike retaining mechanism. Nat Chem Biol 2015;11:847–54.
Guida V, Sinibaldi L, Pagnoni M, et al. A de novo proximal 3q29 chromosome microduplication in a patient with oculo auriculo vertebral spectrum. Am J Med Genet A 2015;167A:797–801.
Artavanis-Tsakonas S, Muskavitch MA. Notch: the past, the present, and the future. Curr Top Dev Biol 2010;92:1–29.
Penton AL, Leonard LD, Spinner NB. Notch signaling in human development and disease. Semin Cell Dev Biol 2012;23:450–7.
Louvi A, Artavanis-Tsakonas S. Notch and disease: a growing field. Semin Cell Dev Biol 2012;23:473–80.
South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 2012;23:458–64.
Ye YZ, Zhang ZH, Fan XY, et al. Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer. Med Oncol 2013;30:595.
Donnem T, Andersen S, Al-Shibli K, et al. Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer 2010;116:5676–85.
Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707–17.
Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148–59.
Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012;13:679–92.
Merlo A, Herman JG, Mao L, et al. 5’CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686–92.
Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503–6.
Duruisseaux M, Esteller M. Lung cancer epigenetics: from knowledge to applications. Semin Cancer Biol 2018;51:116–28.
Seok Y, Lee WK, Park JY, et al. TGFBI promoter methylation is associated with poor prognosis in lung adenocarcinoma patients. Mol Cells 2019;42:161–5.
Vaissière T, Hung RJ, Zaridze D, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res 2009;69:243–52.
Bi H, Liu Y, Pu R, et al. CHST7 gene methylation and sex-specific effects on colorectal cancer risk. Dig Dis Sci 2019;64:2158–66.
Lin S, Liu Y, Goldin LR, et al. Sex-related DNA methylation differences in B cell chronic lymphocytic leukemia. Biol Sex Differ 2019;10:2.
Dunford A, Weinstock DM, Savova V, et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet 2017;49:10–6.